Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoi…


Faeces transplant as treatment for Crohn's disease

Crohn’s disease is a complicated chronic disorder, the complexity of which has only become clear during the last decade. It has become increasingl…

POPULAR TAGS

Galapagos finally managed to close long awaited deal

Written by DS on in the category news with the tags , , .


Earlier this year, AbbVie turned down its deal with Galapagos for co-development and commercializiation of the drug filgotinib for treatment of reumathoid arthritis. Last week, Galapagos announced that filgotinib also has great potential against Crohn's disease. This news did not pass unnoticed; Galapagos managed to close a new deal with Gilead Sciences for co-development and commercialization of filgotinib, and it is giant!

Galapagos will receive 725 million dollars, of which 300 dollars as a license fee and 425 million dollars equity investment. It can also receive up to 1.35 billion dollars in milestone payments. Gilead will be responsible for manufacturing and worldwide marketing and sales activities.

“Gilead shares our goal of rapidly delivering these therapies to patients,” says Onno Van de Stolpe, CEO of Galapagos. “The co-development and co-promotion aspects of this collaboration bring us into the next phase of the company's evolution."

"This partnership represents an opportunity to add complementary clinical programs to our growing inflammation research and development efforts," adds Norbert Bischofberger, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. The companies will jointly collaborate on the global development of filgotinib, starting with the initiation of Phase 3 trials in RA.

Read more about: , , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoi…


Faeces transplant as treatment for Crohn's disease

Crohn’s disease is a complicated chronic disorder, the complexity of which has only become clear during the last decade. It has become increasingl…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation Biowin V-Bio Ventures UGent Flanders.bio Janssen Itera Life Science KU Leuven Turnstone GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.